Loading...
•
Mar 31, 2020
Crinetics Q1 2020 Earnings Report
Crinetics reported first quarter 2020 financial results and provided a corporate update.
Key Takeaways
Crinetics Pharmaceuticals reported positive interim results for its ACROBAT Edge Phase 2 trial of oral paltusotine in acromegaly treatment and completed a public offering, raising $107.9 million in net proceeds. The company's pipeline advancements and focus on paltusotine for acromegaly and NETs were also highlighted.
Reported positive interim results from ACROBAT Edge Phase 2 trial of paltusotine in acromegaly patients, showing maintenance of IGF-1 levels.
Discontinued new enrollment in the ACROBAT Evolve trial to focus on paltusotine development.
Completed a public offering in April, raising approximately $107.9 million to strengthen the balance sheet.
Advanced pipeline programs, including oral nonpeptide ACTH antagonist and SST5 agonist, with Phase 1 trials planned for late 2020 or early 2021.
Forward Guidance
Crinetics is focused on advancing its pipeline, particularly paltusotine, through key milestones, including Phase 3 trials and Phase 2 trials. The company anticipates PK/PD data from human proof-of-concept studies in the first half of 2021.
Positive Outlook
- Potential for interim data results to be consistent with final results.
- Potential benefits of paltusotine for acromegaly patients.
- Potential to initiate a pivotal Phase 3 trial of paltusotine in acromegaly.
- Planned expansion of the paltusotine development program to include the treatment of patients with NETs.
- Anticipated timing of topline data for Edge and Evolve and the initiation of proof-of-concept Phase 1 trials and timing of PK/PD data for its other development programs.
Challenges Ahead
- Interim results of a clinical trial do not necessarily predict final results.
- Potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...